The impact of osimertinib ’ line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance

Until lately, the 1st-line treatment for patients with an advanced stage non-small cell lung cancer (NSCLC) and a mutation in the epidermal growth factor receptor (EGFR) gene, included 1st-generation tyrosine kinase inhibitors (TKIs) for example gefitinib and erlotinib, and the 2nd-generation TKI, afatinib, which were all found to have superior efficacy compared with standard platinum-based chemotherapy treatment [1,2]. Although an initial response is often seen; most patients develop an acquired resistance after a median of 9-15 months[3 –5].

Source: Lung Cancer - January 14, 2021 Category: Cancer & Oncology Authors: Vered Fuchs, Laila Roisman, Waleed Kian, Levin Daniel, Julia Dudnik, Hovav Nechushtan, Iris Goldstein, Addie Dvir, Lior Soussan-Gutman, Roxana Grinberg, Roni Gillis, Nir Peled Source Type: research